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KESAN PERENCATAN PENYEBARAN OLEH KOMBINASI ASID GALIK 
DAN SISPLATIN TERHADAP PROLIFERASI SEL HELA. 
ABSTRAK 
 
Disebabkan pelbagai kesan sampingan dalam rawatan kemoterapi telah mendorong 
banyak penyelidikan berkaitan produk kimia hasilan semulajadi dijalankan untuk 
merawat pelbagai jenis kanser. Sejenis polifenol, asid galik telah dilaporkan dalam kajian 
terdahulu mampu untuk melawan pertumbuhan sel kanser. Justeru, kajian ini bertujuan 
untuk mengkaji kesan perencatan penyebaran sel kanser servik, HeLa yang dirawat 
dengan kombinasi asid galik dan sisplatin. Dalam kajian ini, asid galik digabungkan 
dengan agen antikanser, sisplatin. Migrasi sel, pencerobohan sel dan proliferasi sel diukur 
dengan asai penyembuhan luka gores, asai pencerobohan Transwell dan pembentukan 
koloni masing-masing. Selepas 24 jam asai penyembuhan luka gores, rawatan gabungan 
menunjukkan pengurangan kadar penyembuhan luka secara signifikan dimana 43.08 ± 
6.21% luka telah diisi dengan sel HeLa dalam perbandingan dengan luka gores kumpulan 
rawatan kawalan. Kombinasi asid galik dan sisplatin juga menunjukkan pengurangan 
signifikan terbesar terhadap keupayaan pencerobohan sel HeLa pada 44.55 ± 6.04% 
dalam perbandingan dengan kumpulan rawatan kawalan diukur dengan asai 
pencerobohan Transwell. Kombinasi asid galik dan sisplatin menurunkan proliferasi sel 
HeLa secara signifikan melalui asai pembentukan koloni. Akan tetapi, kesan yang 
dihasilkan hasil daripada kombinasi kedua-duanya menunjukkan hasil yang lebih baik 
daripada rawatan tunggal asid galik dan sisplatin. Oleh itu, kajian lanjutan samada in vivo 
atau in vitro adalah diperlukan untuk menguatkan penemuan ini seperti penglibatan laluan 




METASTATIC INHIBITORY EFFECT OF GALLIC ACID COMBINED 
WITH CISPLATIN ON HELA CELLS PROLIFERATION. 
ABSTRACT 
 
Due to the multiple adverse effects of chemotherapy treatment, more researches with natural 
product discovery has been conducted to treat various types of cancer. A polyphenol 
derivative, gallic acid, was previously reported to combat the growth of cancer cells. Hence, 
this study aims to assess the metastatic inhibitory effect of gallic acid combined with cisplatin 
against HeLa cells. Cell migration, cell invasion and cell proliferation were measured by 
scratch-wound healing assay, Transwell invasion assay and colony formation assay, 
respectively. After 24-hour of scratch-wound healing assay, the combined treatment showed 
significant decrease in wound closure rate where 43.08 ± 6.21% of the wound was filled by 
the HeLa cells in comparison to control wound width. Combination of gallic acid and 
cisplatin also exerted a significant decrease in the number of invaded cells at 44.55 ± 6.04% 
as compared to the control group by Transwell invasion assay. Gallic acid and cisplatin were 
able to significantly reduce the proliferation HeLa cells by colony formation assay. However, 
the effect that was produced by their combination was greater than that of each agent alone. 
Hence further study either in vitro and in vivo is required to strengthen the current findings 
such as research regarding the involvement of PI3K/AKT/mTOR signaling pathway in 









1.1 Background of the study 
 
Cervical cancer is a “woman’s disease” mostly caused by human papillomavirus 
(HPV) via sexually acquired infection. World Health Organization (WHO) reported cervical 
cancer as the fourth most frequent cancer in women worldwide with 7.5% mortality rate in 
2018. In addition, cervical cancer appeared to be the third estimated prevalence of cancer in 
2018 within 3 years’ time periods from 2015 to 2018. Asian women were the major 
contributor to these cases with 55.3% followed by Africa and Europe. Patients with cervical 
cancer commonly have irregular or abnormal vaginal bleeding, fatigue, weight loss due to 
decrease appetite and a single swollen leg (WHO, 2020). At present, prevention measures of 
cervical cancer include three different screening tests consisting of visual inspection of the 
cervix with acetic acid (VIA), Papanicolaou (Pap) smear, and HPV DNA test for 




Cervical cancer treatment comes with several modalities including surgery, 
chemotherapy and radiotherapy. Surgery might be the best choice of treatment as it removes 
infected tissue from the body (Schnipper et al., 2015). Not to mention, immunotherapy also 
one of the treatments where it stimulates patient’s own immune response to recognize and 
kill the cancer cells without damaging normal cells (Atashzar et al., 2020).  However, the 
late diagnosis of cervical cancer in the advanced stage leads to high mortality rates in low- 
and middle-income countries (Dunyo et al., 2018). Neoadjuvant chemotherapy had been used 
before surgery and radiation therapy. Neoadjuvant therapy is a treatment that being delivered 
and used as a first step to reduce tumor size before a primary treatment is given. However, 
neoadjuvant therapy can only be used before the tumor blood flow after surgery and radiation 
therapy is interrupted. A large tumor might be difficult to treat using neoadjuvant 
chemotherapy and have a high chance to develop micro-metastatic disease in cancer patient 
(Park et al., 2004). The ability of tumor cell to detach from its primary tumor, migrate, invade 
and form a new secondary tumor is truly a challenge for scientist and pharmacist to develop 
a drug. Advanced stage of cervical cancer treatment focused more on stopping and killing 
malignant cells from dividing and growing. At this stage, radiation and chemotherapy are the 
only option in combating the disease (NCI, 2020). However, those treatments come with 
several adverse side effects in the short and long term.  
 
Cisplatin, a common chemotherapy agent approved by Food and Drug 
Administration (FDA), is prescribed intravenously to treat patients with advanced ovarian 
cancer, testicular cancer, and bladder cancer. Moreover, cisplatin also used off-label to treat 
advanced or recurrent cervical cancer and other type of cancers. However, there was 
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emerging evidence about the dark side of cisplatin therapy towards cancer patients. Being in 
the market for more than 38 years, cisplatin was said to cause major nephrotoxicity and may 
lead to drug resistance which is the top health worry (Manohar and Leung, 2018). Following 
the disadvantages of these conventional drugs, many researchers have been focusing their 
interest in natural compound as anti-cancer agent. 
 
Gallic acid (GA; 3, 4, 5-trihydroxybenzoic acid) is a natural compound found in many 
types of plants. It is a phenolic organic compound and a part of tannin where it becomes a 
powerful antioxidants (Subramanian et al., 2015). The first curative property of GA was used 
as antimalarial in 1953 (Thompson et al., 1953). On top of that, GA was proven to inhibit the 
growth of HeLa cervical cancer cells via apoptosis and necrosis (You et al., 2010). 
 
Nowadays, combination therapy using two or more therapeutic agents is becoming 
more popular among researchers. Combination therapy gives more efficacy as it can 
synergistically act on the same tumor cell with different approaches to kill the cells. 
Synergistic effect means that combination of two or more drugs exhibits a greater effect than 
their individual effect alone.  It is important for two drugs to achieve the synergistic effect as 
synergistic interaction enables the use of lower drug concentrations thus reducing adverse 
side effect. Single therapy or known as monotherapy commonly leads to the development of 
drug resistance and several adverse effects. Hallmarks of the cancer were stupendous, and 
some characteristics were still in mystery. The development of drug resistance typically 
occurred because of their characteristics. Trastuzumab was the drug used as chemotherapy 
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agents to treat HER2-positive breast cancer tumors. However, to date, single used of 
trastuzumab have low efficacy as the cancer cells have developed resistance towards the drug 
(Housman et al., 2014). Thus, combination trastuzumab with doxorubicin plus 
cyclophosphamide followed by paclitaxel plus trastuzumab and total of 1 year of trastuzumab 
was used at present as research showed that both drugs gave a high efficacy effect in 
combating breast cancer tumor (Schnipper et al., 2015).  
 
1.2 Problem statement 
 
In this current study cisplatin with the combination of natural product, GA was 
selected to study the effect towards, cervical cancer cell proliferation. Combination of 
cisplatin and other natural plant sources have been studied to reveal the inhibitory effect on 
cancer cells. However, the use of cisplatin combined with GA as a treatment for cervical 
cancer is poorly understood. As both treatments have shown many successful effects on other 
cancer cells, thus it is beneficial to study and evaluate the effects of GA alone and in 
combination with cisplatin on cell proliferation and metastasis ability in human cervical 
cancer cell line (HeLa cells). Furthermore, cisplatin was reported to cause many side effects 
on cancer patient when taken as a sole medication. Thus, it is essential to find another 






1.3 Justification of the study 
 
This study was conducted to provide evidence of a potential alternative combination 
chemotherapy that could be an option to treat cervical cancer patients. Cancer cells have 
numerous abilities (Hallmarks of cancer) to evade and change its approaches to escape from 
chemotherapy agents. On that account, researchers were searching for ways to overcome the 
problems.  Neoadjuvant therapy can only be used before the tumor blood flow after surgery 
and radiation therapy is interrupted. In consequence, combination of chemotherapy agents is 
necessary to reduce the development of drug resistance in cancer patients. Multimodality 
treatments increase the magnitude of therapeutic efficacy even at low and optimum dose. 
These allow different agents to work on different targets with different mechanisms but 
achieving the same anti-cancer effect. Hence, it is critical to find the right alternative 
combination for future use of cancer therapy. 
 
1.4 Objectives of the study 
 
1.4.1 General objective 
 





1.4.2 Specific objectives 
 
1. To determine the migration capability of HeLa cells treated with gallic acid, cisplatin 
and combination of gallic acid plus cisplatin. 
2. To determine the invasion capability of HeLa cells treated with gallic acid, cisplatin 
and combination of gallic acid plus cisplatin. 
3. To determine the reproducibility of HeLa cells treated with gallic acid, cisplatin and 




1. There is significant effect on migration capability of HeLa cells treated with gallic 
acid, cisplatin and combination of gallic acid with cisplatin. 
2. There is significant effect on invasion capability of HeLa cells treated with gallic 
acid, cisplatin and combination of gallic acid with cisplatin. 
3. There is significant effect on proliferation capability of HeLa cells treated with gallic 









2.1 Overview of cancer 
 
 Cancer is known as a disease that caused human cells to divide infinitely (National 
Institute of Health, 2015). Normal cells have the capability to divide. Its capabilities for cell 
division depends on its response towards certain stimuli. For example, cells that are damaged 
or dead will trigger the normal cells to divide in order to replace the damaged or dead cells. 
The underlying mechanism in which cells normally divide and grow depends on the presence 
of proto-oncogene. However, this gene can be mutated or altered to produce a gene which is 
termed by "oncogene" that will produce tumor cells or cancer cells. This genetic mutation 
can be passed from parents to offspring. This is the internal factor that caused cancer in an 
individual. Moreover, external factors that might cause cancer in a patient are exposure 
towards chemical, radiation and viruses from environment (Krishnan et al., 2020). Based on 




 Cancer is divided into four stages. Stage I indicates the early stage of cancer that is 
localize at one part of the body and does not spread to the other nearby lymph node or organs. 
Stage II is a bit advance than stage I where cancer has spread into the lymph node but not the 
other parts of the body. Cancer at this stage can be cured with the same treatment for stage I 
cancer which are surgery or radiation therapy. Stage III refers to a locally advance cancer 
where cancer has growth into specific size, and sometimes it can grow beyond its original 
location and metastasize to lymph node, other part of organs and tissues. Stage IV is the 
serious disease that need immediate expert care. At this stage, cancer has metastasized to the 
distant organ and usually found after one year of cancer surgery or therapy (Cancer Treatment 
Centre of America, 2020). 
 
 Cancer has its own mechanistic strategies to remain inside human body. Six 
hallmarks of cancer were proposed by Hanahan and Weinberg in the year 2000 (termed as 
Hallmarks I) which were self-sufficiency in growth signal, insensitivity to anti-growth 
signals, tissue invasion and metastasis, limitless replicative potential, sustained angiogenesis 
and evading apoptosis. Figure 2.1 shows the illustration used to represent Hallmarks of 
cancer. Later in 2011, they added another two hallmarks (termed as Hallmarks II): 
reprogramming energy metabolism and evading immune response, and two enabling traits: 
genome instability and mutation, and tumor-promoting inflammation (Yousef and Aanei, 
2017). Mostly normal cells require a stimulus from growth factor to start proliferating. 
However, cancer cells owned their self-sufficiency in growth signals by mimicking growth 
signal from normal cells. Cancer cells also able to produce its own endogenous growth signal 






















Figure 2. 1: Acquired capabilities of cancer - Hallmark I (Hanahan and Weinberg, 2000).  
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2.2 Cervical cancer 
 
Cervix is a cylinder-shape of tissue that connect vagina and uterus. Cervix is divided 
into two portions which are endocervix and ectocervix. Internal and external os are parts of 
uterus as shown in Figure 2.2. Endocervix extents from internal os (the opening into the 
uterus) inside of the uterus to external os. Ectocervix is a location at an external os that opens 
to allow passage from vagina to uterus (Bhatla et al., 2018). According to WHO, mortality 
rate of cervical cancer in Asia population contribute to 168 411 cases in 2018. Approximately 
90% of deaths from cervical cancer occurred in low- and middle-income countries.  
 
Cervical cancer is the possible outcome of genital infection with high-risk human 
papillomavirus (HPV) and is preceded by a phase of persistent HPV infection during which 
the host immune system fails to eliminate the virus (De Jong et al., 2004). Cervical cancer is 
one of the common malignant tumors in women worldwide. Even though there are a lot of 
advance screening and preventive measure, the prognosis of cervical cancer is especially 
poor and the rate of advanced or recurrent patients is barely 10% to 20% with 1 year of 
survival (Wang et al., 2018). Cervical cancer comes with a few symptoms listed by WHO: 
irregular periods, abnormal vaginal bleeding after sexual intercourse, back, leg or pelvic pain, 






Figure 2. 2: Anatomy of uterus (Anatomy Note, 2019).  
 
Cervical cancer is characterized into four stages and each stage is divided into several 
parts. Stage I is where the cancer was formed in the cervix. It is divided into IA and IB based 
on the size of the tumor and the deepest of the tumor invasion point. Stage II of cervical 
cancer has spread to the upper two-third of the vagina or to the tissue around uterus. It is 
divided into IIA and IIB based on the distant cancer has spread. Stage III of cervical cancer 
has spread to the lower third of the vagina and/or to the pelvic wall, and/or has caused kidney 
problems, and/or involves lymph nodes. Stage III is divided into IIIA, IIIB, and IIIC based 
on the distant cancer has spread. Stage IV of cervical cancer has spread to the other parts of 
organs other than pelvis . This stage is divided into IVA and IVB based on the location cancer 
12 
 
has spread (American Cancer Society, 2020). Figure 2.3 showed the illustration of cervical 
cancer stage IVA that has spread to the urinary bladder and rectum.  
 
Figure 2. 3:  Image of stage IVA of cervical cancer (NCI,2020). 
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2.3 Cancer metastasis 
 
Tissue invasion and metastasis were one of the other six hallmarks that become a 
major problem to handle when happened. At this stage, cancer cells capable to invade tissue 
and organ in the body, move to another part of the body and caused secondary tumor. By that 
reason, to date, researchers were more focusing to search for a various method that can help 
to block and contained the cells from metastasize (Hanahan and Weinberg, 2000). Most of 
the cancer, metastatic cancer was named as stage IV (four) cancer. Furthermore, the 
metastatic cancer was named after the primary cancer. If cancer starts grew from liver cancer 
and metastasized to brain, the cancer is term as liver cancer not brain cancer. It is because 
when cancer cells are viewed under microscope, the feature of metastatic cells are similar 
with the primary cancer cell not the site where it was found. Cancer can spread to other parts 
of the body and the most common sites where cancer spreads are bone, liver and lung.  
 
According to NCI, cancer metastasis spreads in a series of steps which could be 
summarized in Figure 2.0. Normally, metastatic cancer does not show symptoms. However, 
the symptoms can arise depend on the size and location of the metastatic cancer. Brain cancer 
patients may be having a headaches, seizures or dizziness; lung cancer patients may be having 
a shortness of breath; bone cancer patients may be having a pains or fractures; liver cancer 
patients may be having a jaundice or swelling in the belly. Metastatic cancer can be hard to 
treat. Even though some metastatic cancer can be cured with current treatment, but most of 
them cannot. In most cases where the cancer can no longer be controlled, palliative care is 
14 
 





Figure 2. 4: Illustration of a series of steps in cancer metastasis (Jiang et al., 2015). 
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2.4 Anticancer drug for cervical cancer 
 
According to National Cancer Institute (NCI), there is a list of approved drugs used 
to treat cervical cancer which are avastin (bevacizumab), bleomycin sulfate, hycamtin 
(topotecan hydrochloride), heytruda (pembrolizumab), mvasi (biosimilar to avastin), 
pembrolizumab, and topotecan hydrochloride (NCI, 2019). Pembrolizumab is a generic name 
for a drug name Keytruda®. It is a monoclonal antibody used to treat multiple type of 
diseases such as recurrent or metastatic cervical cancer, recurrent or metastatic head and 
recurrent or metastatic neck squamous cell carcinoma and non-small cell lung cancer. 
Pembrolizumab is inject intravenously through vein over 30 mins every 3 weeks 
(ChemoCare, 2002). Pembrolizumab specifically targets the immune checkpoint PD-1, 
blocking its interaction with its ligands and demonstrated durable antitumor activity and 
manageable safety in patients with advanced cervical cancer (Chung et al., 2019).  
 
Development of new blood vessels is termed as angiogenesis. Cancer tumors require 
oxygen and nutrient for cell function and survival. Hence, cancer cells will seize the way to 
develop new blood vessel for its own.  Imbalance of angiogenic inhibitor and angiogenic 
activator will caused cancer. In cancer, angiogenic activator might be higher than angiogenic 
inhibitor. Bevacizumab is a monoclonal antibody and anti-angiogenesis drug given by 
intravenous injection. It is prescribed to patient with metastatic colon, breast, and 
glioblastoma cancer. According to Minion et al. (2015), bevacizumab was used to treat 
cervical carcinogenesis. Tumor-associated angiogenesis can be inhibited by targeting the 
17 
 
vascular endothelial growth factor (VEGF) pathway with the humanized monoclonal 
antibody bevacizumab. 
 
Tigecycline is from the class of glycylcyclines. It is a FDA-approved antibiotic drug 
that can be used for cervical cancer and targeting Wnt (Wingless-related integration site)/β-
catenin represents a potential therapeutic strategy in cervical cancer (Li et al., 2015). 
Cisplatin is a cytotoxic chemotherapy drug that is classified as an alkylating group. It is used 
as a treatment for advanced bladder cancer, metastatic ovarian cancer, and metastatic 
testicular cancer. Fuertes et al. (2012) reported that cisplatin induces its cytotoxic properties 
through binding to nuclear DNA and subsequent interference with normal transcription and 




Cisplatin is a cytotoxic chemotherapy drug prescribed intravenously in cervical 
cancer patient. It is a platinum agent with chemical formula of Cl2H6N2Pt 
(diamminedichloroplatinum). To date, there is no cisplatin in the form of tablet or pill. 
According to Fuertes et al. (2012), biochemical mechanism of action (MOA) of cisplatin 
involves the binding of cisplatin to the DNA in cell nucleus. The binding will interfere with 
normal transcription and/or DNA replication. Thus, lead to the cytotoxic process (program 
cell death) of the cancer cells. The first step in MOA of cisplatin is cisplatin accumulation. 
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Intravenous injection of cisplatin diffused in tissue and transport throughout the blood vessel. 
In the blood, plasma protein act as a carrier where it binds to cisplatin and transport to its 
target. When reach the cell, most cisplatin enters the cell via passive diffusion, and other via 
facilitated and active transport. Upon arriving the cell, less than 1% of cisplatin will bind to 
DNA target while others bind with other cellular constituent inside the cytoplasm. N7 atom 
of guanine and adenine in the DNA are the most reactive site for metal binding. Thus, bind 
with the platinum agent, cisplatin and resulted in the changes of DNA structure (Fuertes et 
al., 2012).  
 
Chemotherapy with cisplatin was revealed to induce apoptosis in cancer cells as a 
mode of cell death (Kilic et al., 2015). In spite of that, resistant cancer cell lines showed 
necrotic cell death characteristic after treatment with cisplatin (Gonzalez et al., 2001). In the 
past, cisplatin had been documented as the most effective drug used as neoadjuvant 
chemotherapy to treat cervical cancer (Grigsby, 2001; Iwasaka et al., 1998). Cisplatin was 
practically and widely used as chemotherapy agent in cervical cancer (Kilic et al., 2015). 
However, there has also been information on other chemo-drug for cervical cancer such as 
pembrolizumab (Chung et al., 2019) and bevacizumab (Minion et al., 2015). Cytotoxicity 
property of cisplatin exerts an important anticancer effect but causes several side effects such 
as nausea, vomiting, low blood count, kidney toxicity, and ototoxicity (ChemoCare, 2002).  
Initially, a positive response usually happened in patients treated with cisplatin. However, 
when cancer relapse cisplatin does not give the same curative effect. It is probable that 
cisplatin resistance has aroused. This resistance was said to result from epigenetic changes at 
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molecular and cellular levels (Shen et al., 2012). These pharmacological drawbacks have 
stimulated the exploration to find a better chemotherapy agent. 
 
2.6 Role of natural product in cervical cancer treatment 
 
Natural product has become more popular among researchers for their various 
curative potential of diseases. This is partly due to the presence of several undesired adverse 
side effects on current chemotherapy. Nowadays, scientists are more attracted to conduct 
research related to natural compound as an anti-cancer drug. Zaman et al., (2016) 
demonstrated that the usage of nanoformulation-curcumin in cervical cancer cells exert anti-
cancer effect as it effectively inhibits cell growth, induces apoptosis and arrests the cell cycle 
at G1-S transition phase. Curcumin nanoformulation was found accumulate in high 
concentration in cervical cancer cells due to its smaller size. This study proved that 
nanotechnology can be used in future as an initiative approach to develop a better anti-tumor 
drug.  
 
Another study about tualang honey (TH) was said able to reduce the mitochondrial 
membrane potential (Δψm) and induce mitochondrial apoptotic pathway in the breast and 
cervical cancer cell lines (Fauzi et al., 2011).  Alabsi and his friends (2012) in their study 
indicated that goniothalamin, a natural occurring styryl-lactone able to induce apoptosis in 
HeLa cancer cells. Their flow cytometry analysis revealed accumulation of HeLa cells 
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arrested in S-phase when treated with gonithalamin and annexin V/PI double staining showed 
there is increase in the presence of phosphotidylserine (PS). PS translocate from the inner 
plasma membrane to the outer cellular activity indicates the process of apoptosis where the 
cancer cells undergo program cell death.  
 
Another study proved that baicalein, active compound of Scutellaria baicalensis 
Georgi induces apoptosis of HeLa cells via mitochondrial and death receptor pathways (Peng 
et al., 2015). Phenolic acid is divided into hydroxycinnamic acids and hydroxybenzoic acids. 
The most important compound from hydroxybenzoic acid class is gallic acid (GA). It was 
said that GA might be accountable in inhibiting angiogenesis in cancer cells (Moga et al., 
2016). Furthermore, GA induced apoptotic cell death in HeLa cells by annexin V-staining 
cells method accompanied by reactive oxygen species (ROS) increase and glutathione (GSH) 
depletion (You et al., 2010).  
 
2.7 Gallic acid 
 
Gallic acid (GA) is a trihydroxybenzoic acid in which the hydroxy groups are at 
positions 3, 4, and 5. Its molecular formula is C7H6O5 or C6H2(OH)3COOH and its structure 
was shown in Figure 2.3. It has a role as an astringent, an antioxidant, antineoplastic agent, 
and apoptosis inducer. GA can be richly found in gallnuts, sumac, oak bark, green tea, grapes, 
strawberries, pineapples, bananas, lemons, witch hazel, red and white wines, apple peels and 
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orange juice (You et al., 2010; Arabi et al., 2017). Figure 2.4 illustrates the sources of GA 
and its derivatives that can be found. GA was reported to have pharmacological activities 
where it inhibits cell proliferation, cell viability, cell invasion, angiogenesis and induces 






























Figure 2. 6: Sources of gallic acid and its derivatives (personal collection). 
 
Moreover, Zhao and Hu (2013) in their study demonstrated GA as an anti-cancer 
agent where it inhibits cell viability in a dose-dependent manner, cell proliferation, cell 
invasion and suppression of ADAM metallopeptidase domain 17 (ADAM17), estimated 
glomerular filtration rate (EGFR), phosphorylated Akt (p-Akt) and phosphorylated Erk (p-
Erk) expression. Besides, GA was mentioned to have a high efficacy, lower dosage, and less 
side effect when combined with paclitaxel for cervical cancer cells treatment. Their 
combination showed a very promising future in pharmacological industry. However, a future 
studies need to be done to properly demonstrated the effect in animal models (Aborehab and 
Osama, 2019).  
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Liu et al. (2020) indicated that GA possess anti-inflammatory effect on rats by 
weakening lipopolysaccharide-induced neuroinflammation, oxidative stress and protein 
conjugation. In addition, GA also inhibited lipopolysaccharide (LPS)-induced programmed 
cell deaths of nigrostriatal dopaminergic neurons of the rat brain, demonstrated 
neuroprotective effect in central nervous system (CNS) neurogenerative diseases. As 
eloquently stated by Mahboob et al. (2020), GA was valuable for its biological and 
pharmacological activities. It shows many biological effects which include anti-bacterial, and 
anti-acanthamoebic. GA able to inhibit 83% of trophozoites and 69% of cysts in 
Acanthamoeba triangularis with no adverse side effects. Furthermore, encapsulated 
nanoparticles of GA shown to exhibit less cytotoxicity compared to normal GA in human 
fetal lung fibroblasts MRC-5 cancer cells. This means that GA in encapsulated nanoparticles 
form could play a major role delivering drugs in the future.  
 
GA also is a strong anti-oxidants and apoptotic agent and it was used by researchers 
in studies regarding many degenerative diseases like atherosclerosis, cardiovascular disease, 
aging, and inflammation (Shabani et al., 2020). Jin et al. (2018) in his study revealed that 
GA able to improve cardiac dysfunction and fibrosis in pressure overload-induced heart 
failure where it decreases left ventricular end-diastolic and end-systolic diameter also 






2.8 Combination therapy 
 
Combination therapy in cancer is not a new method used nowadays. In most cases, 
practitioners combine surgery, radiation therapy, immunotherapy and chemotherapy depends 
on the profile cases. Focusing on chemotherapy, researchers are now striving to search for a 
new combination chemotherapy or a better drugs that can reduce the multidrug resistance. 
Park and his collegues (2004) reported that 39 out of 43 cervical cancer patients showed 
90.7% response rate towards neoadjuvant chemotherapy of paclitaxel-cisplatin in phase II 
trial. In his study, toxicity of chemotherapy was reduced by optimizing the drug dosage. 
Besides, treatment effectiveness was increased in a shorter time by combining paclitaxel with 
cisplatin and modifying treatment interval.  
 
In this study, searching for alternative treatment agent to treat advanced and 
metastatic cervical cancer were priorities. The combination of high doses of vitamin C and 
cisplatin could decrease the adverse effect of chemotherapy (Reddy et al., 2001). 
Combination therapy of cisplatin and radiotherapy increases survival rate of patient with 
locally advanced cervical cancer, large stage IB tumors (prior to surgery) and high-risk early-
stage disease (following surgery) (Lukka et al., 2002). The combination of paclitaxel with 
cisplatin to be used in neoadjuvant chemotherapy appears to be tolerated and very energetic 
in cervical cancer (Park et al., 2004). Mitochondria is a place for apoptosis intrinsic pathway. 
According to Wang and his friends (2016), combination treatment of GA and cisplatin exhibit 
